New research shows Polatuzumab Vedotin combined with R-CHP offers promising results for Diffuse Large B-Cell Lymphoma patients with durable benefits.
Discover how TP53 mutations and MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma and the promising combination strategies to overcome it.